Acetyl octapeptide-3

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

Limited human evidence. Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Mechanistic claims are largely based on laboratory hypotheses and formulation research. A compound-specific preclinical evidence base sufficient to predict clinical outcomes was not identified in this review.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJul 22, 2026

  Cosmetic / topical

  Acetyl octapeptide-3 is catalogued as a substance and used in cosmetics, which generally do not receive FDA premarket approval. No FDA-approved drug containing it was identified.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• Acetyl hexapeptide-8Both are topical cosmetic peptides studied in formulation-specific anti-wrinkle contexts.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   FDA GSRS record for acetyl octapeptide-3

   U.S. Food and Drug Administration Global Substance Registration System. Acetyl octapeptide-3 substance record.

   U.S. Food and Drug Administration · Accessed Jul 22, 2026 · Regulatory source

   Open source
2. 2

   Clinical study of a multi-ingredient microneedle patch containing acetyl octapeptide-3

   Shin JY, et al. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Annals of Dermatology. 2024;36(4).

   PubMed-indexed primary study · Published Aug 1, 2024 · Accessed Jul 22, 2026 · Clinical study

   Open source
3. 3

   FDA authority over cosmetics

   U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated.

   U.S. Food and Drug Administration · Published Dec 20, 2022 · Accessed Jul 22, 2026 · Regulatory source

   Open source